Nas­daq threat­ens to delist Taysha Gene Ther­a­pies

Taysha Gene Ther­a­pies, a com­pa­ny that shelved a lengthy list of drug pro­grams and gen­er­at­ed con­tro­ver­sy by thwart­ing fam­i­ly-led re­boots, has re­ceived a delist­ing warn­ing from the Nas­daq Glob­al Se­lect Mar­ket.

The com­pa­ny, ac­cord­ing to its reg­u­la­to­ry fil­ing, re­ceived the no­tice last week for its fail­ure to meet the min­i­mum val­ue of list­ed se­cu­ri­ties. It has 180 days to re­gain com­pli­ance.

In 2020, Taysha raised $157 mil­lion through an IPO, part of a plan to take the fi­nan­cial bur­den off fam­i­lies that sparked re­search at UT South­west­ern. Less than two years lat­er, Taysha shelved all but two of its more than 20 pro­grams, mak­ing the com­pa­ny a sym­bol of the wider strug­gle to com­mer­cial­ize gene ther­a­pies. Last sum­mer, Taysha took a con­tro­ver­sial le­gal ap­proach by block­ing fam­i­lies from restart­ing paused pro­grams else­where.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER